Physician profile
Sona Kamat
NPI 1407896129
$267,812.90
in general payments reported to CMS, 2019-2025
43 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $50K · 2021: $23K · 2022: $30K · 2023: $29K · 2024: $16K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $16K · Food and Beverage: $8,346 · Travel and Lodging: $6,972 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,800.00 |
| Consulting Fee | $16,255.00 |
| Food and Beverage | $8,345.78 |
| Travel and Lodging | $6,971.76 |
| Education | $236.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80,674.77 | 2019-2025 | |
| Lilly USA, LLC | $67,372.21 | 2019-2025 | Olumiant, Zepbound, Taltz |
| Amgen INC. | $51,542.17 | 2019-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $28,638.83 | 2019-2025 | |
| Ucb, INC. | $18,730.72 | 2019-2024 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $5,008.47 | 2019-2022 | |
| Horizon Therapeutics Plc | $4,123.29 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $2,297.46 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Janssen Global Services, LLC | $1,400.00 | 2021 | |
| Pfizer INC. | $1,189.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,010.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $955.57 | 2022-2025 | Saphnelo |
| Novo Nordisk INC | $778.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $588.86 | 2019-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $456.72 | 2019-2023 | Actemra |
Show all 41 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sona Kamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.